Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

Metabolic imaging reveals anti-angiogenic (AA) therapy mechanisms in glioblastoma (GBM) GBM is the most common and aggressive type of malignant primary brain tumors (glioma). Patients with GBM have less than 5% survival at 5 years with the best existing treatment and progress is desperately needed t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ovidiu C. Andronesi, Morteza Esmaeili, Ronald J. H. Borra, Kyrre Emblem, Elizabeth R. Gerstner, Marco C. Pinho, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, S. Percy Ivy, Patrick Y. Wen, Dan G. Duda, Rakesh Jain, Bruce R. Rosen, Gregory A. Sorensen, Tracy T. Batchelor
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cff8891abc634b19b196fe665c1e1ac0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

Ejemplares similares